Location Availability

Hospital Affiliation

Northside Hospital, Northside Cherokee Hospital and Northside Hospital-Forsyth

Dr. Reddy is a board-certified medical oncologist and hematologist with expertise in treating solid tumors and blood cancers.  He completed training in internal medicine at St. Lukes-Roosevelt Hospital of Columbia University and was a fellow in oncology and hematology at Emory University School of Medicine.

Dr. Reddy is a managing partner of Atlanta Cancer Care and he is the principle investigator in multiple cancer clinical trials.  He is a member of the Northside Hospital Lung Cancer Work Group, Lung Cancer Research Group, Genitourinary Work Group and Gastrointestinal Malignancy Work Group.


Board Certifications: Internal Medicine, Medical Oncology and Hematology

Clinical Fellowship: Emory University, Atlanta, GA, Division of Hematology/Oncology, 2000-2003

Internship and Residency: St. Luke’s-Roosevelt Columbia University, New York, N.Y. 1997-2000

Medical School: St. George’s University, 1993-1997 Undergraduate: B.A., University of Virginia, 1992

Hospital Affiliations: Northside Hospital, Northside Forsyth Hospital and Northside Cherokee Hospital

Education & Training


Emory University School of Medicine – Hematology and Oncology


St. Luke’s-Roosevelt Hospital Center – Internal Medicine

Medical School

St. George’s University School of Medicine

Research & Clinical Trials

Dr. Reddy is the principle Investigator for the following clinical trials:

  • A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study) www.clinicaltrials.gov/ct2/show/NCT03377556
  • A Phase II Study of ABBV-399 (Process II) in Patients with c-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
  • Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials http://www.clinicaltrials.gov/ct2/show/NCT02194738
  • Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
  • Adjuvant Nivolumab in Resected Lung Cancers (ANVIL): A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
  • Study of Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome (NCT#NCT02269592)

Northside Hospital researchers and Atlanta Cancer Care physicians work alongside respected industry partners and nationally recognized clinical trial networks to provide you with access to the latest treatments and prevention methods being tested through clinical trials.

Professional Memberships

  • Georgia Society of Clinical Oncology


Dr. Reddy has published articles on multiple myeloma, head and neck cancer, and lung cancer.

Clinical Interests

  • breast cancer, aerodigestive and hematology malignancies

Find a physician